Case Report: Microangiopathic Hemolytic Anemia With Normal ADAMTS13 Activity.
ADAMTS13
breast cancer
disseminated intravascular coagulation
hemolytic anemia
thrombotic microangiopathy
thrombotic thrombocytopenic purpura
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2021
2021
Historique:
received:
30
07
2020
accepted:
06
01
2021
entrez:
19
3
2021
pubmed:
20
3
2021
medline:
20
3
2021
Statut:
epublish
Résumé
Thrombotic microangiopathies (TMAs) include a heterogeneous group of diseases characterized by abnormalities in the vessel walls of arterioles and capillaries resulting in microvascular thrombosis that typically presents with a microangiopathic hemolytic anemia (MAHA) and severe thrombocytopenia. We describe here the case of an 82-year-old woman, who came to our attention for a clinical condition consistent with thrombotic microangiopathy. Even if initially highly suggestive for a thrombotic thrombocytopenic purpura (TTP), the elevated ADAMTS13 activity together with the alteration of the main coagulation parameters (D-dimer elevation, fibrinogen consumption, slightly prolonged prothrombin time), induced us to consider several other diseases in the differential diagnostic process. The case evolved toward a suspected overlapped secondary hemophagocytic syndrome, though the hyperferritinemia was finally interpreted within the frame of a cytokine storm. After a complex diagnostic workup, the clinical and biochemical parameters guided us toward the diagnosis of a cancer-related microangiopathic hemolytic anemia (CR-MAHA) secondary to a relapsing breast cancer with multiple metastatic localizations. Prednisone 1 mg/kg body weight was started, and several units of fresh frozen plasma were infused, obtaining a good control of the hemolysis. No specific oncological therapies were, however, possible, due to the older age and the critically compromised general condition of the patient; therefore, after clinical stabilization, the patient was discharged for treatment in a palliative care Hospital.
Identifiants
pubmed: 33738292
doi: 10.3389/fmed.2021.589423
pmc: PMC7960662
doi:
Types de publication
Case Reports
Langues
eng
Pagination
589423Informations de copyright
Copyright © 2021 Osti, Beschin, Goldin, Guidolin, Panero, Sartori, Parisi, Cantini, Pizzolo, Olivieri and Friso.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Int J Lab Hematol. 2014 Aug;36(4):439-43
pubmed: 24261329
Thromb J. 2016 Oct 4;14(Suppl 1):19
pubmed: 27766045
N Engl J Med. 2020 Dec 3;383(23):2255-2273
pubmed: 33264547
N Engl J Med. 2014 Aug 14;371(7):654-66
pubmed: 25119611
Case Rep Oncol. 2019 Jan 23;12(1):104-108
pubmed: 31043946
Breast Care (Basel). 2011 Dec;6(6):441-445
pubmed: 22419897
Br J Haematol. 2015 Dec;171(5):836-44
pubmed: 26314936
J Formos Med Assoc. 2002 May;101(5):362-7
pubmed: 12101856
Medicine (Baltimore). 2012 Jul;91(4):195-205
pubmed: 22732949
Lancet Haematol. 2017 Apr;4(4):e157-e164
pubmed: 28259520
BMC Nephrol. 2016 Jan 06;17:4
pubmed: 26739581
Thromb Res. 2012 Apr;129 Suppl 1:S122-6
pubmed: 22682122
Springerplus. 2016 May 20;5(1):684
pubmed: 27350919